| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.18▼ | 4.18▼ | 4.18▼ | 4.11▼ | 4.21▼ |
| MA10 | 4.17▼ | 4.21▼ | 4.22▼ | 4.28▼ | 4.02▲ |
| MA20 | 4.22▼ | 4.23▼ | 4.25▼ | 4.25▼ | 3.85▲ |
| MA50 | 4.08▲ | 3.89▲ | 3.82▲ | 3.95▲ | 4.20▼ |
| MA100 | 3.77▲ | 3.76▲ | 3.76▲ | 3.82▲ | 3.93▲ |
| MA200 | 4.22▼ | 4.36▼ | 4.34▼ | 4.22▼ | 3.96▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.024▼ | -0.029▼ | -0.033▼ | -0.055▼ | 0.081▲ |
| RSI | 49.598▼ | 51.138▲ | 51.953▲ | 47.657▼ | 51.894▲ |
| STOCH | 55.788 | 49.267 | 48.035 | 30.095 | 73.729 |
| WILL %R | -54.167 | -54.167 | -54.167 | -66.031 | -29.545 |
| CCI | -39.834 | -15.109 | -23.159 | -89.019 | 53.309 |
|
Wednesday, June 04, 2025 08:13 AM
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor ...
|
|
Wednesday, May 14, 2025 09:10 AM
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of ...
|
|
Monday, May 12, 2025 11:20 AM
Given the high risks and speculative nature of Genfit's ACLF pipeline, I rate GNFT as a Hold, suitable for a barbell portfolio. The attention on Genfit turns to its pipeline, which is composed of ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/06/25 | 4.1484 | 4.18 | 4.10 | 4.10 | 1,507 |
| 12/06/25 | 4.305 | 4.305 | 4.03 | 4.03 | 9,181 |
| 11/06/25 | 4.32 | 4.32 | 4.17 | 4.20 | 12,920 |
| 09/06/25 | 4.24 | 4.29 | 4.0484 | 4.20 | 1,677 |
| 06/06/25 | 4.24 | 4.26 | 4.025 | 4.025 | 2,761 |
| 05/06/25 | 4.47 | 4.47 | 4.47 | 4.47 | 190 |
| 04/06/25 | 4.46 | 4.6054 | 4.46 | 4.47 | 997 |
| 03/06/25 | 4.51 | 4.51 | 4.51 | 4.51 | 354 |
| 02/06/25 | 4.54 | 4.54 | 4.2785 | 4.2785 | 2,084 |
| 30/05/25 | 4.48 | 4.53 | 4.48 | 4.51 | 2,299 |
|
|
||||
|
|
||||
|
|